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Abstract We engineered a hepatoma cell line that produces an 
up-regulation of insulin in response to CAMP, dexamethasone, 
and retinoic acid, and a down-regulation in response to insulin. 
We devised a regulatory secretion system by placing proinsulin 
DNA under the regulatable promoter for phosphoenolpyruvate 
carboxykinase (PEPCK). To assess the ability to regulate insulin 
secretion, we used the rat hepatoma cell line, H4IIE. The H4IIE 
cells secreted immunoreactive insulin (IRI) constantly at a level 
of l-3 fmoll106 cells/h. IRI increased approximately two-fold 
upon stimulation with 0.5 mM CAMP and five-fold with the 
addition of the CAMP-dependent phosphodiesterase inhibitor 
IBMX, as compared to baseline IRI secretion. IRI increased 1% 
fold by l-500 nM dexamethasone together with CAMP and 
IBMX. Addition of exogenous insulin to the culture medium 
significantly decreased insulin mRNA expression on Northern 
blot. 
Key words: Insulin production; PEPCK promoter; H4IIE; 
Gene therapy; Proinsulin processing 
1. Introduction 
Two types of cells are available for engineering insulin-pro- 
ducing surrogate cells for diabetes gene therapy: neuroendo- 
crine and non-neuroendocrine cells. Neuroendocrine cells are 
equipped with a processing mechanism that converts a pro- 
peptide into a mature bioactive peptide, and a regulatory 
secretion system by which a mature peptide is secreted in 
response to extracellular stimuli. Thus, when neuroendocrine 
cells, such as the anterior pituitary corticotroph-derived endo- 
crine cells AtT20, are used for ‘diabetes gene therapy, the 
primary focus has been to engineer an insulin secretion mech- 
anism that responds to a physiological range of glucose 
stimuli [l-3]. On the other hand, when non-neuroendocrine 
cells are used as insulin-producing cells, the cells need to be 
engineered with a processing mechanism and a regulatory 
secretion system. Several attempts have been made to confer 
insulin-producing capabilities on non-neuroendocrine cells 
such as the mouse fibroblast-derived Ltk- cells [4-61. The 
Ltk- cells transfected with insulin DNA produced proinsulin, 
but not mature insulin, independent of extracellular stimuli 
because these cells are not equipped with a processing mech- 
anism or a regulatory secretion system. These issues must be 
addressed before non-neuroendocrine cells can be used as in- 
sulin-producing surrogate cells for diabetes gene therapy. 
In pancreatic p cells, the processing of proinsulin into ma- 
ture insulin consists of two enzymatic reactions: cleavage by 
*Corresponding author. Fax: (81) (272) 20-8896. 
E-mail: tstake @sb.gunma.ac.jp 
the prohormone convertases PC2 and PC3 (also named PCl), 
and trimming of the carboxyl terminal basic amino acids from 
the newly exposed B-chain of insulin by carboxypeptidase H 
(CPH) [7-91. These two proteolytic reactions are specific to 
secretory granule-containing neuroendocrine cells [&lo]. In- 
deed, pioneering work by Moore et al. has demonstrated 
that human proinsulin can be correctly processed to insulin 
in the endocrine cell line AtT20, but not in the fibroblast cell 
line Ltk- [4]. However, when we replaced the processing sites 
of proinsulin with those cleavable by the yeast Kex2 family 
endoprotease furin, the non-neuroendocrine cell lines, includ- 
ing COS-7, HepG2, CHO, and NIH3T3, produced insulin 
that was the same size as synthetic human insulin [11,12]. 
Next, the furin-cleaved proinsulin required the removal of 
basic residues by carboxypeptidases for its maturation. 
Although non-neuroendocrine cells expressed different quan- 
tities of CPH mRNA, these cells contained considerable levels 
of carboxypeptidase activity. The insulins resulting from these 
cell lines were eluted as a single peak at the same position on a 
cation-exchange chromatography column as mature insulin 
[13]. Thus, non-neuroendocrine cells are able to produce cor- 
rectly processed insulin if proinsulin is first mutated to possess 
furin-cleavable processing sites. 
For developing an insulin expression system that can be 
regulated by extracellular stimuli, the most desirable system 
is to use glucose as a stimulator. Insulin may be used as an 
alternative regulator for down-regulating its expression. Be- 
cause non-neuroendocrine cells do not carry secretory gran- 
ules and secrete proteins and peptides through a constitutive 
pathway without their retention in the cytoplasm [8], the reg- 
ulatory step available for the production of insulin is limited 
to the gene transcription level. The expression of many genes 
is regulated by glucose [l&16]. For the regulatory expression 
of these genes, target cells must have both a glucose transpor- 
ter type 2 and a glucokinase in order to respond to a physio- 
logical range of glucose concentrations [3]. To meet these 
criteria, the primary cultured hepatocytes are the cells of 
choice for assessing the expression of glucose-regulated genes. 
Hepatocytes are relatively inefficient, however, for DNA 
transfer by conventional gene transfer methods [17]. Further- 
more, hepatocyte culture cell lines with glucose transporter 
type 2 and glucokinase are not available at the present time. 
Thus, we attempted to generate a system in which expression 
is regulated by insulin, using a hepatoma cell line and the 
phosphoenolpyruvate carboxykinase (PEPCK) promoter 
[ 18-201. The PEPCK is expressed in hepatocytes and catalyzes 
oxaloacetate to phosphoenolpyruvate by removing a phos- 
phate from GTP. This enzyme facilitates hepatic glucose pro- 
duction. In diabetic subjects this enzyme is highly active due 
to the lack of insulin. The PEPCK promoter is known to be 
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up-regulated by CAMP, glucocorticoids, and retinoic acid 
(RA), and is down-regulated by insulin [20-221. For assessing 
the PEPCK promoter activity, several hepatocyte culture cell 
lines are available, including H4EII and FT02B. Thus, we 
examined the insulin production using a PEPCK promoter 
plus an insulin DNA construct in H4EII cells. 
Experimental gene therapy for diabetes was first attempted 
by Selden et al. by expressing a metallothionein promoter plus 
a human insulin DNA construct in mice [5]. This expression 
vector was introduced into Ltk- cells together with a thymi- 
dine kinase gene. The resultant Ltk+ cells that produced 
proinsulin were injected intraperitoneally into diabetic C3H 
mice, which were immunosuppressed with the use of rabbit 
anti-mouse thymocyte serum and dexamethasone. The mice 
exhibited normoglycemia a week after the implantation of 
proinsulin-producing Ltk+ cells, but died from the growth 
of Ltkf cells or from hypoglycemia [6]. Other types of experi- 
mental gene therapy trials have been attempted using liver 
cells with a liposome-Sendai virus gene transfer system or a 
retroviral system [23,24]. None of the gene therapy trials, 
however, utilized efficient, regulatable insulin expression sys- 
tems. 
In the present study we demonstrate that insulin production 
in H4EII cells under the PEPCK promoter was up-regulated 
by CAMP, IBMX, and dexamethasone, and down-regulated 
by insulin. When we expressed the proinsulin with furin-cleav- 
able processing sites in this cell line, the cells produced mature 
insulin. 
2. Materials and methods 
2. I. Construction of a regulatable insulin expression vector 
A regulatable insulin expression vector was made by modifying a 
previously reported insulin expression vector [12]. The previous vector 
contains a rat insulin gene I with or without furin-cleavable sites [12]. 
We inserted a thymidine kinase (TK) promoter (-105 to +51) as a 
basal promoter, and placed a PEPCK promoter (-598 to -31) before 
the TK promoter. The PEPCK promoter was amplified by PCR using 
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Fig. 1. Disappearance of IRI from the culture medium of H4IIE 
cells. The intact H4IIE cells were cultured in the presence of human 
insulin or human proinsulin. Proinsulin was added to the culture 
medium at a final concentration of 5 nM at the 0 time point. Insu- 
lin was added at final concentrations of 0.2, 1, and 5 nM. At each 
indicated time, samples were collected from the medium for IRI 
measurement. Percent of residual IRI in the medium is expressed 
relative to initial IRI (0 time point). Proinsulin 5 nM, closed circles; 
insulin 5 nM, open triangles; 1 nM, closed triangles; 0.2 nM, open 
circles. Bars indicate standard deviation. 
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Fig. 2. Time course of IRI production from the cells transformed 
with the P2/TK/PI DNA. IRI production was chased for 48 h. To 
examine the regulated IRI production one group of cells were cul- 
tured in the presence of 0.5 mM cAMP+O.S mM IBMX+SOO nM 
dexamethasone (open circles), the other cultured in the absence of 
the stimulants (closed circles). Bars indicate standard deviation. 
from Dr. Daryl Granner) [25]. We constructed six different expression 
vectors with multiple copies of PEPCK promoters. 
2.2. Cell culture and DNA transfection 
The rat hepatoma cell line H4IIE (ATCC CRL 1548) was used in 
this study. This cell line is frequently used for PEPCK promoter 
analysis with a variety of regulators [20-221. The H4IIE cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma, 
St. Louis, MO) with 6% fetal bovine serum (FBS; Gibco, Grand 
Island, NY) at 37°C in 5% COa. Glucose concentration in the medium 
was 25 mM. Cells were transformed using a liposome method with 
DOTAP N-[l-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium- 
methyl sulfate (Boehringer Mannheim, Indianapolis, IN). Because 
the vectors contained a neomycin-resistant gene, the native or mutant 
proinsulin-expressing cells were selected by maintaining the culture in 
a medium containing the neomycin analogue G418 (Gibco; 0.5 mg/ 
ml). 
2.3. Radioimmunoassay 
Immunoreactive insulin (IRI) in the culture medium was detected 
using an insulin immunoassay kit (Amersham Japan, Tokyo, Japan). 
The antibody in this kit recognizes both proinsulin and mature insulin 
on an equimolar basis. 
2.4. Regulation of IRI production 
To observe the regulatable production of IRI, we added the follow- 
ing chemicals to the culture medium: the CAMP analogue N6,2,0- 
dibutyryl cyclic adenosine monophosphate (dbcAMP), the CAMP-de- 
pendent phosphodiesterase inhibitor 3-isobutyl-l-methylxanthine 
(IBMX), dexamethasone, retinoic acid, human insulin. All chemicals 
were purchased from Sigma, St. Louis, MO. The H4IIE cells were 
incubated with each chemical for 18 h. unless otherwise stated. 
2.5. Northern blot 
The isolation of the total cellular RNA from each cell line was 
performed as described previously [12]. The total RNA was electro- 
phoresed on a 1.2% agarose gel, and transferred to a nylon membrane 
(Amersham). Hybridization was performed with a probe of the rat 
insulin gene I DNA fragment (350 bp) labeled with [a-32P]deoxy-CTP 
by the random priming procedure. The membrane was exposed to an 
X-ray film (Eastman Kodak, Rochester, NY) with an intensifying 
screen at -80°C. 
2.6. Gel filtration 
Gel filtration chromatography was carried out on a 1.0 X 120 cm 
column (Bio-Rad) containing Sephadex G-50 supertine gel (Pharmacia 
LKB, Piscataway, NJ), equilibrated with 100 mM acetic acid, to ana- 
lyze the apparent size of insulin secreted into the culture medium. 
Eluted samples were assayed for IRI with RIA. 
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3. Results 
3.1. Regulatable production of IRI 
In previous studies we noted that IRI from the mutant 
insulin-expressing cells was much lower than that from the 
native proinsulin-expressing cells [11,12]. It may be that the 
culture cells adsorb mature insulin by insulin receptor- 
mediated endocytosis, thereby secreting less insulin into the 
culture medium. We tested this possibility by adding proinsu- 
lin and insulin into the H4IIE culture medium. Mature insulin 
disappeared quickly from the culture medium, whereas proin- 
sulin decreased much more slowly than mature insulin until 
Fig. 3. Regulated production of IRI with CAMP, dexamethasone, 
and retinoic acid. The H4IIE cells transformed with the P2flWPI 
DNA were cultured with or without the stimulants. After 18 h incu- 
bation, samples were collected from the culture medium for IRI 
measurement. A: The H4IIE cells were stimulated with CAMP alone 
or cAMP+O.S mM IBMX. CAMP was added to the medium at final 
concentrations of 50-500 mM. Closed circles: culture with CAMP 
alone; open circles: culture with cAMP+O.S mM IBMX. Bars indi- 
cate standard deviation. B: The cells were stimulated with dexa- 
methasone alone or dexamethasone+0.3 mM cAMP+O.S mM 
IBMX. Dexamethasone was added to the medium at final concen- 
trations of l-500 nM. Closed circles: culture with dexamethasone 
alone ; open circles : culture with dexamethasone+0.3 mM 
cAMP+O.S mM IBMX. Bars indicate standard deviation. Inset: 
blowup of IRI production curves between 0 and 5 nM dexametha- 
sone. C: The cells were stimulated with retinoic acid alone or reti- 
noic acid+0.3 mM cAMP+O.S mM IBMX. Retinoic acid was added 
to the medium at final concentrations of 0.2-5.0 mM. Closed circle, 
cultus:e with retinoic acid alone; open circles: culture with retinoic 
acid+0.5 mM cAMP+O.S mM IBMX. Bars indicate standard devia- 
tion. 
t 
48 h after insulin or proinsulin was added to the H4IIE cul- 
ture medium (Fig. 1). Thus, for the assessment of regulated 
IRI production, we used the cells transformed with the proin- 
sulin expression vector first, then evaluated the autoregulatory 
feature of insulin production using the native type insulin- 
producing cells transformed with the insulin expression vec- 
tor. 
Among the six cell lines we established, the greatest increase 
of IRI was observed in the cell line expressing a vector with 
two PEPCK promoters+TK promoter+proinsulin DNA (P21 
TK/PI) when stimulated with 0.5 mM dbcAMP+O.S mM 
IBMX+SOO nM dexamethasone. Thus, we used this cell line 
for the assessment of regulatable IRI production. Firstly, we 
examined IRI production over time. A low level (l-3 fmol/106 
cells/h) of IRI was produced over time by the proinsulin-pro- 
ducing cells. Upon stimulation with dbcAMP+IBMX+dexa- 
methasone, IRI production increased linearly until 18 h after 
the stimulation, then plateaued gradually towards the 48-h 
point (Fig. 2). Thus, we evaluated IRI production using the 
medium after 18 h in culture. 
IRI production gradually increased 2-fold with increasing 
amounts of dbcAMP (up to 500 uM; Fig. 3A). When the 
CAMP-dependent phosphodiesterase inhibitor, IBMX, was 
added to dbcAMP, the increase in IRI was more marked. 
IBMX alone (up to 1.5 mM) did not increase IRI production; 
thus, 0.5 mM IBMX was used in the present study. In the 
presence of IBMX, 50 uM dbcAMP induced approximately a 
2.5-fold increase in IRI and 300 uM dbcAMP induced a 
greater than 3-fold increase as compared to treatment with 
300 mM dbcAMP alone (Fig. 3A). Although the addition of 
0.5 mM IBMX induced a similar increase between 50 and 500 
uM dbcAMP, 300 uM dbcAMP+O.S mM IBMX induced a 
relatively high increase. Thus, we used the dose of 300 uM 
dbcAMP in the treatment study. 
The addition of dexamethasone (l-5 nM) induced approxi- 
mately a 3-fold increase. Increasing the dose of dexametha- 
sone (up to 500 nM) did not induce further increases (Fig. 
3B). The addition of dexamethasone with 300 uM dbcAMP 
and 0.5 mM IBMX produced an enhanced increase in IRI 
production, which reached approximately 4-fold over the level 
induced by 5 nM dexamethasone alone, and approximately 
18-fold over the IRI level produced with no stimulants (Fig. 
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3B). The greatest increase of IRI was obtained at 50 and 100 
nM dexamethasone with 300 pM dbcAMP+O.S mM IBMX. 
Thus, we used 100 nM dexamethasone for the combined stim- 
ulants. Retinoic acid (up to 1.0 FM) was also effective in 
increasing IRI production (Fig. 3C). The combination of 
dbcAMP and IBMX was effective in enhancing the efficacy 
of retinoic acid. The combination increased IRI production 
approximately 7-fold over the basal production without stim- 
ulation. 
3.2. Suppressive effect of insulin on insulin mRNA expression 
It is not possible to evaluate the inhibitory effects of insulin 
on IRI production unless RIA of rat proinsulin C peptide is 
available. Thus, we measured insulin mRNA expression in the 
H4llE cells with the increase of exogenous insulin (0, 0.1, 1.0, 
10 nM) in the culture medium. The expression of insulin 
mRNA decreased with increased levels of an exogenous insu- 
lin dose (Fig. 4A). Even with 0.1 nM insulin, the message was 
so inhibited as to be barely visible on the blot. However, the 
inhibition by exogenous insulin was less effective when the 
stimulants were added simultaneously with insulin. The insu- 
lin message stayed unchanged with 0, 0.1, and 1.0 nM exo- 
genous insulin, but the message decreased distinctly with 10 
nM of insulin in the culture medium. When the cells were 
treated with insulin for 8 h, then with the stimulants but with- 
out insulin for another 18 h, the inhibitory effect of insulin 
continued extensively (Fig. 4, lane -8 h). Thus, overdose of 
insulin is effective in suppressing the insulin mRNA expres- 
sion. 
3.3. Regulated insulin production from the native or mutant 
proinsulin-expressing cell line 
Since we found that the proinsulin expression vector carry- 
ing the PZ/TK/Pl DNA regulated the expression in the H4llE 
cells, we replaced the mutated proinsulin DNA encoding the 
furin-cleavable sites for the native proinsulin DNA in the 
expression vector (P2/TK/l). As expected, the cells expressing 
this vector produced a more mature type of insulin (Fig. 5B). 
Approximately 60% of the IRI was eluted at the native insulin 
position on gel filtration chromatography, suggesting that the 
H4llE cells may contain a high level of furin [12]. In contrast, 
the P2/TK/Pl-expressing cells produced IRI, more than 90% 
of which corresponded to the proinsulin position on the gel 
(Fig. 5A). 
IRI production from the P2/TWl-expressing cells was also 
regulated in a similar manner to that from the proinsulin- 
expressing cells by dbcAMP and dexamethasone, as shown 
in the left panel of Fig. 6. However, the increase of IRI by 
the stimulants was less than that observed in P2/TWPl-ex- 
pressing cells. For example, IRI was increased only about 6- 
fold more by the stimulants dbcAMP+lBMX+dexamethasone 
than that from the cells without stimulation (ABD in Fig. 
6A). In contrast, the increase of proinsulin was 15-fold 
more by the same stimulants than that from the non-stimu- 
lated cells (ABD in Fig. 6B). Moreover, the IRI produced 
from the P2/TK/l_expressing cells was about a third to a fifth 
of that of the P2/TK/Pl_transformed cells producing native 
proinsulin probably due to endocytosis depicted in Fig. 1. 
4. Discussion 
To engineer non-neuroendocrine cells for use as insulin-pro- 
A No stimulants With the stimulants 
Exogenous insulin -8 h 
0 0.1 1.0 lOnM 0 0.1 1.0 10 10 nM 
418s 
B 18s and 285 ribosomal RNAs 
Fig. 4. Northern blot analysis of the insulin mRNA expression with 
exogenous insulin in the culture medium. The H4IIE cells trans- 
formed with P2/TK/PI DNA were cultured with exogenous insulin 
for 18 h at final concentrations of 0, 0.1, 1.0, 10 nM in the presence 
or absence of the stimulants; 0.3 mM cAMP+O.S mM IBMX+lOO 
nM dexamethasone. Insulin was added to the culture medium to- 
gether with the stimulants. Total RNAs of 20 lg from each cell 
group were used in this experiment. A: The left panel illustrates the 
blotting from the cell culture in the absence of the stimulants, the 
right panel that in the presence of the stimulants. 18s represents the 
corresponding size of ribosomal RNA. The far right lane marked 
-8 h indicates that the cells were cultured in the presence of 10 nM 
insulin for 8 h, then for 18 h with the stimulants but without insu- 
lin. B: 28s and 18s ribosomal RNA bands stained with ethidium 
bromide. 
ducing surrogate cells, the cells must be able to: (1) process 
proinsulin, (2) regulate insulin secretion and (3) efficiently ac- 
cept transfer of the insulin expression vector. Proinsulin was 
processed using ubiquitously distributed endoprotease furin. 
For the processing of proinsulin by furin, the dibasic residues 
between the B chain and C peptide and between C peptide 
and the A chain were mutated to tetrabasic residues to allow 
for furin cleavage [11,12,26,27]. 
The secretion of insulin from non-endocrine cells should be 
increased by a high concentration of glucose and decreased by 
a low concentration of glucose. Because the regulating step for 
insulin secretion is limited to the level of gene transcription in 
non-neuroendocrine cells, we examined several candidate pro- 
moters with a glucose-responsive element for regulating insu- 
lin production. For example, we used a promoter for rat L- 
type pyruvate kinase because it contains two glucose-respon- 
sive elements [28]. But an attempt to regulate insulin expres- 
sion by this promoter was not successful because glucose ac- 
tivation of the glucose-responsive element was weak, even if 
multiple elements were placed ahead of the basic promoter. 
Thus, we used a PEPCK promoter because this promoter is 
known to be activated by CAMP, glucocorticoids, and retinoic 
acids, and suppressed by insulin [14]. 
As the first step, we expressed native proinsulin to reduce 
insulin receptor-mediated endocytosis because proinsulin has 
a much lower affinity for the receptors than does mature in- 
sulin, and does not suppress the PEPCK promoter as much as 
mature insulin [29]. DbcAMP, dexamethasone, or their com- 
bination stimulated the increase of IRI production only 2-3- 
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fold. The addition of IBMX to dbcAMP, or to dbcAMP+- 
dexamethasone, however, induced a significant increase in IRI 
production (Fig. 3). In previous studies using H4IIE cells, 
PEPCK promoter activity increased 8-16-fold over basal ac- 
tivity when stimulated by the addition of 0.1 mM 8-(4-chlor- 
ophenylthio)-cAMP+O.5 mM dexamethasone, and reduced 
80-90% from the maximal activity by the addition of 5 nM 
insulin in several assay systems, including dot blot hybridiza- 
tion and CAT activity assay [20,29]. Thus, our data using 
insulin as a reporter are consistent with previous reports. 
Although insulin is known to suppress PEPCK promoter ac- 
tivity [20,21], insulin-induced inhibition of insulin is difficult to 
measure in our engineered cells. Thus, Northern blot analysis 
was used to assess decreased expression of insulin mRNA by 
exogenous insulin in culture medium (Fig. 6). We observed a 
decreased expression of insulin mRNA with a high dose of 
exogenous insulin (10 nM). 
Another obstacle to overcome is the efficient gene transfer 
in hepatocytes [ 171. For this purpose a retroviral or adenoviral 
transfer method, or a liposome-mediated transfer method may 
be suitable [23,24,30]. We are currently in the process of ex- 
amining these methods using diabetic animals. The insulin 
expression vector we devised may be useful for an accessory 
10 20 30 40 
Fraction number 
Fig. 5. Gel filtration profiles of IRI in the culture medium of the 
PZ/TK/PI- or P2/TK/I_expressing cells. The concentrated media were 
applied to Sephadex G-50 superfine gel columns (1.0 X 120 cm) equi- 
librated with 0.1 M acetic acid. Fractions of 1.5 ml were collected 
and measured for IRI by RIA. A: IRI from the P2/TK/PI-expres- 
sing cells; B: IRI from the P2/TK/I_expressing cells. Molecular size 
was calibrated with blue dextran (Vo), potassium ferricyanide (Vt), 
and synthetic human insulin (I). Similar elution profiles were ob- 
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Fig. 6. Regulatable IRI production from the insulin-producing cells 
and proinsulin-producing cells. The cell line transformed with the 
P2/TK/I DNA was used as insulin-producing cells. IRI production 
from the insulin-producing cells was compared with that from the 
proinsulin-producing cells transformed with the P2ffWPI DNA. Pa- 
nel A illustrates the IRI production from the insulin-producing cells, 
panel B illustrates IRI production from the proinsulin-producing 
cells. A, 0.3 mM CAMP; B, 0.5 mM IBMX; D, 500 nM dexa- 
methasone. 
insulin-producing system in gene therapy or in hybrid-type 
artificial islets for the treatment of diabetes mellitus. 
Acknowledgements: This work was supported by grants-in-aid from: 
the Ministry of Education, Science and Culture; the Terumo Life 
Science Foundation; the Japanese Diabetes Foundation; and the To- 
kyo Biochemical Research Foundation. D.L. is the recipient of a 
postdoctoral fellowship from the Japan Society for the Promotion 
of Science. We thank the followinp. aeoule: Dr. Darvl K. Granner. 
Department of Physiology and Biophysics, Vanderbilt University 
Medical School, Nashville, TN for providing a rat PEPCK gene pro- 
moter-containing plasmid pPL9-CAT; Dr. Howard C. Towle, De- 
partment of Biochemistry and Institute of Human Genetics, Univer- 
sity of Minnesota, MN for a TK promoter-containing plasmid 
pTKCAT; and Ms. Mina Takei for secretarial assistance. 
References 
[l] Newgard, C.B. (1992) Biotechnology 10, 1112-1120. 
[2] Hughes, S.D., Johnson, J.H., Quaade, C. and Newgard, C.B. 
(1992) Proc. Natl. Acad. Sci. USA 89, 688-692. 
[3] Newgard, C.B. (1994) Diabetes 43, 341-350. 
[4] Moore, H.-P.H., Walker, M.D., Lee, F. and Kelly, R.B. (1983) 
Cell 35, 531-538. 
[5] Selden, R.F., Skoskiewicz, M.J., Russell, P.S. and Goodman, 
H.M. (1987) New Engl. J. Med. 317, 1067-1076. 
[6] Kawakami, Y., Yamaoka, T., Hirochika, R., Yamashita, K., 
Itakura, M. and Nakauchi, H. (1992) Diabetes 41, 956961. 
[7] Smeekens, S.P. (1993) Bio-Technology 11, 182-186. 
[8] Halban, P.A. and Irminger, J.-C. (1994) Biochem. J. 299, 1-18. 
[9] Davidson, H.W. and Hutton, J.C. (1987) Biochem. J. 245, 5755 
582. 
[lo] Orci, L., Ravazzola, M., Starch, M.J., Anderson, R.G.W., Vas- 
salli, J.D. and Perrelet, A. (1987) Cell 49, 8655868. 
1111 Yanagita, M., Nakayama, K. and Takeuchi, T. (1992) FEBS _ _ 
Lett. 511, 55559. _ 
1121 Yanazita. M.. Hoshino. H.. Nakavama. K. and Takeuchi. T. . 1  
(1993) Endocrinology 133, 639-644: ’ 
[13] Nishigori, T., Yanagita, M. and Takeuchi, T. (1996) Peptides 17, 
7899796. 
[14] Granner, D. and Pilkis, S. (1990) J. Biol. Chem. 265, 101733 
10176. 
[15] Clarke, SD. and Abraham, S. (1992) FASEB J. 6, 31463152. 
42 D. Lu et al.IFEBS Letters 399 (1996) 37-42 
[16] Tanaka, M., Katashima, R., Murakami, D., Adzuma, K., Taka- 
hashi, Y., Tomonari, A., Iwahana, H., Yoshimoto, K. and Ita- 
kura, M. (1995) Diabetologia 38, 381-386. 
[17] Ginot, F., Decaux, J.-F., Cognet, M., Berbar, T., Levrat, F., 
Kahn, A. and Weber, A. (1989) Eur. J. Biochem. 180, 289-294. 
[18] Lucas, P.C. and Granner, D.K. (1992) Annu. Rev. Biochem. 61, 
1131-1173. 
[19] McGrane, M.M., Yun, J.S., Patek Y.M. and Hanson, R.W. 
(1992) Trends Biochem. Sci. 17, 4044. 
[20] O’Brien, R.M., Lucas, P.C., Forest, CD., Magnuson, M.A. and 
Granner, D.K. (1990) Science 249, 533-537. 
[21] O’Brien, R.M., Lucas, P.C., Yamasaki, T., Noisin, E.L. and 
Granner, D.K. (1994) J. Biol. Chem. 269, 30419-30428. 
[22] Sutherland, C., O’Brien, R.M. and Granner, D.K. (1995) J. Biol. 
Chem. 270, 15501-15506. 
[23] Kaneda, Y., Iwai, K. and Uchida, T. (1989) J. Biol. Chem. 264, 
1212612129. 
[24] Kolodka, T.M., Finegold, M., Moss, L. and Woo, S.L.C. (1995) 
Proc. Natl. Acad. Sci. USA 92, 3293-3297. 
[25] Petersen, D.D., Magnuson, M.A. and Granner, D.K. (1988) Mol. 
Cell. Biol. 8, 96104. 
[26] Groskreutz, D.J., Sliwkowski, M.X. and Gorman, CM. (1994) 
J. Biol. Chem. 269, 62416245. 
[27] Simonson, G.D., Groskreutz, D.J., Gorman, CM. and Macdon- 
ald, M.J. (1996) Hum. Gene Ther. 7, 71-78. 
[28] Liu, Z., Thompson, K.S. and Towle, H.C. (1993) J. Biol. Chem. 
268, 12787-12795. 
[29] Sasaki, K., Cripe, T.P., Koch, S.R., Andreone, T.L., Petersen, 
D.D., Beale, E.G. and Granner, D.K. (1984) J. Biol. Chem. 259, 
15242215251. 
[30] Cristiano, R.J., Smith, L.C., Kay, M.A., Brinkley, B.R. and 
Woo, S.L.C. (1993) Proc. Natl. Acad. Sci. USA 90, 11548-l 1552. 
